203 related articles for article (PubMed ID: 28652875)
1. Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Klaassen Z; Li K; Kassouf W; Black PC; Dragomir A; Kulkarni GS
Can Urol Assoc J; 2017 Jun; 11(6):173-181. PubMed ID: 28652875
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
4. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder].
Gakis G; Volkmer B; Qvick B; Marteau F; Stenzl A
Urologe A; 2019 Jan; 58(1):34-40. PubMed ID: 29637215
[TBL] [Abstract][Full Text] [Related]
6. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
[TBL] [Abstract][Full Text] [Related]
7. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
10. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
[TBL] [Abstract][Full Text] [Related]
11. Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
Elbæk SK; Andreasen TG; Taber A; Young-Halvorsen K; Neijber A; Jensen JB; Dyrskjøt L
Eur Urol Open Sci; 2023 Dec; 58():37-46. PubMed ID: 38152487
[TBL] [Abstract][Full Text] [Related]
12. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
[TBL] [Abstract][Full Text] [Related]
13. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
15. HAL fluorescence cystoscopy and TURB one year of Romanian experience.
Geavlete B; Mulţescu R; Georgescu D; Jecu M; Geavlete P
J Med Life; 2009; 2(2):185-90. PubMed ID: 20108538
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
[TBL] [Abstract][Full Text] [Related]
17. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Yang LP
Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
[TBL] [Abstract][Full Text] [Related]
18. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
19. Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States.
Lewicki P; Arenas-Gallo C; Qiu Y; Venkat S; Basourakos SP; Scherr D; Shoag JE
Eur Urol Focus; 2022 Jul; 8(4):968-971. PubMed ID: 34711530
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Pietzak EJ
Curr Urol Rep; 2017 May; 18(5):39. PubMed ID: 28324275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]